Indication
As monotherapy for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (cSCC) at high risk of recurrence after surgery and radiation.
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC3019
- Pharmaceutical company
- Regeneron Pharmaceuticals Inc
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC